Liquid biopsy analytics agent

Skill FridrichMethod/awesome-skills/skills/liquid-biopsy-analytics-agent

Curated, auto-synced collection of 2,000+ Claude Code & Codex skills for AI4Protein, bioinformatics, AI development, and academic paper writing. One curl command installs them all.

Install

npx -y skills add FridrichMethod/awesome-skills --skill liquid-biopsy-analytics-agent

Assembled from the repository path, not quoted from the project. Check it against their README if it does not work.

2 things to look at

no licenseNo license file was found in the repository. Code published without one is not open source by default, so using it at work is a question for whoever answers licensing questions where you are.
11 stars11 stars. Stars are a popularity signal and not a quality one, but at this level it is likely that nobody has read this closely except its author, and you would be relying on your own review.

What its author says it does

Copied from the file, not written here

Comprehensive analysis of liquid biopsy data (ctDNA, CTCs) for cancer detection, MRD monitoring, and response tracking.

SKILL.md

5.9 KB, as published. Nobody here has run it

Liquid Biopsy Analytics Agent

The Liquid Biopsy Analytics Agent provides comprehensive AI-driven analysis of blood-based cancer biomarkers. It integrates circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and cell-free RNA for multi-cancer early detection (MCED), minimal residual disease (MRD) monitoring, and treatment response assessment.

When to Use This Skill

For multi-cancer early detection screening from blood samples.
To monitor minimal residual disease (MRD) after curative treatment.
When tracking tumor evolution and resistance during therapy.
For real-time treatment response assessment.
To detect cancer recurrence before clinical or imaging evidence.

Core Capabilities

ctDNA Mutation Analysis: Variant calling, VAF tracking, and clonal evolution from cell-free DNA.
Methylation-Based Detection: cfDNA methylation patterns for cancer detection and tissue-of-origin identification.
CTC Enumeration & Analysis: AI-powered CTC detection, enumeration, and molecular characterization.
Multi-Modal Integration: Combines ctDNA, CTCs, and protein biomarkers with clinical/imaging data.
MRD Monitoring: Ultra-sensitive detection of residual disease post-treatment.
Response Prediction: AI models predicting treatment response from longitudinal liquid biopsy data.

Analyte Types and Applications

Analyte	Detection Method	Clinical Use
ctDNA mutations	NGS, ddPCR	Therapy selection, resistance
ctDNA methylation	WGBS, targeted	MCED, tissue of origin
ctDNA fragmentation	WGS	Cancer detection
CTCs	CellSearch, microfluidics	Prognosis, monitoring
Exosomes	Immunocapture	Biomarker cargo
cfRNA	RT-qPCR, NGS	Gene expression

Workflow

Input: Liquid biopsy data (ctDNA variants, methylation, CTC counts, protein markers).
Quality Control: Assess sample quality, input DNA amount, background noise.
Variant Analysis: Call mutations, calculate VAF, filter artifacts (CHIP).
Multi-analyte Integration: Combine biomarker signals using ML fusion.
Clinical Interpretation: Generate actionable insights for treatment decisions.
Longitudinal Tracking: Model dynamics for response assessment and recurrence detection.
Output: Cancer detection probability, MRD status, treatment recommendations, clonal evolution.

Example Usage

User: "Analyze longitudinal ctDNA data from this lung cancer patient to assess treatment response and detect resistance."

Agent Action:

python3 Skills/Oncology/Liquid_Biopsy_Analytics_Agent/lb_analyzer.py \
    --ctdna_variants longitudinal_ctdna.vcf \
    --timepoints week0,week4,week8,week12 \
    --tumor_markers cea_values.csv \
    --baseline_tissue baseline_tumor.maf \
    --analysis response_resistance \
    --chip_filter true \
    --output lb_report/

AI/ML Models

Multi-Cancer Early Detection (MCED):

Methylation-based classifiers (sensitivity ~50-80% at 99% specificity)
Multi-analyte combination models
Tissue-of-origin prediction
Integration with imaging and clinical risk

MRD Detection:

Tumor-informed (personalized panels from tissue)
Tumor-agnostic (fixed panels, methylation)
Detection limits: 0.01% - 0.001% VAF

Response Prediction:

Longitudinal VAF dynamics modeling
Bayesian evolution frameworks
Time-to-progression prediction

Clonal Hematopoiesis Filtering

Critical challenge in liquid biopsy interpretation:

Gene	Prevalence	Action
DNMT3A	30-40% of CHIP	Filter if VAF stable, no tumor context
TET2	20-30%	Filter if VAF stable
ASXL1	10-15%	Filter if VAF stable
TP53	5-10%	Context-dependent (tumor vs CHIP)
Matched WBC	Gold standard	Subtract germline/CHIP variants

Commercial Platforms (Reference)

Platform	Technology	Application
Guardant360	ctDNA NGS	Therapy selection
FoundationOne Liquid	ctDNA NGS	Comprehensive profiling
Galleri	Methylation	MCED screening
Signatera	Tumor-informed	MRD monitoring
CellSearch	CTC	FDA-cleared enumeration

Clinical Decision Points

Treatment Selection: Actionable mutations (EGFR, ALK, ROS1, BRAF)
Response Assessment: ctDNA clearance correlates with outcomes
Resistance Detection: Emerging resistance mutations (T790M, C797S)
Recurrence Monitoring: Lead time of 3-6 months over imaging

Prerequisites

Python 3.10+
NGS variant calling pipelines
Methylation analysis tools
Machine learning frameworks

Related Skills

ctDNA_Analysis - For detailed ctDNA workflows
Tumor_Clonal_Evolution - For evolutionary analysis
MRD_Detection - For residual disease focus

Limitations and Considerations

False positives: CHIP, benign tumors, inflammation
False negatives: Low shedding tumors, early stage
Technical variability: Pre-analytical factors critical
Cost: Multi-analyte panels expensive

Author

AI Group - Biomedical AI Platform